Supplier News

Simtra BioPharma Solutions Expands Sterile Fill/Finish Manufacturing Site

February 28, 2024

The company is investing more than $250 million into its Bloomington, Ind. Manufacturing site.

CSL Licenses Cytegrity Lentiviral Vector Production System to Genezen

February 27, 2024

CSL will share access to Cytegrity, its proprietary stable production system for lentiviral vector production, with Genezen.

AstraZeneca Completes Acquisition of Icosavax

February 21, 2024

AstraZeneca has completed its acquisition of Icosavax, gaining the IVX-A12 vaccine candidate that targets RSV and hMPV.

GSK Seeks to Expand its Respiratory Biologics Portfolio with Aiolos Acquisition

February 21, 2024

GSK is expanding its respiratory biologics portfolio with its acquisition of Aiolos Bio and its novel therapy, AIO-001.

Nelson Labs Creates Center of Excellence for Parenteral and Ophthalmic Drug Manufacturing

February 15, 2024

The company’s Itasca, Ill., facility will offer chemistry, manufacturing, and controls analytical testing support.

Samsung Biologics Partners with LegoChem Biosciences on ADCs

February 12, 2024

Under the new partnership, Samsung Biologics will develop and manufacture an antibody for a LegoChem Biosciences ADC candidate.

Purolite and Repligen Launch New Affinity Resin

February 07, 2024

Purolite and Repligen have commercially launched a new CH1 affinity resin for the purification of specialized mAbs.

Quantum-Si Launches Platform Enhancements for Protein Sequencer

February 06, 2024

The addition of another amino acid recognizer as well as improvements in surface chemistry, reagents, and software expand the proteome coverage of Quantum-Si’s Platinum sequencing platform.

Biovian and 3P Biopharmaceuticals Combine to Form 3PBIOVIAN

February 05, 2024

The CDMOs are joining together to offer end-to-end development and manufacturing services for protein expression systems and viral vectors in Europe.

Novo Holdings to Acquire Catalent in Deal Valued at $16.5 billion

February 05, 2024

Novo Holdings has entered into a merger agreement with Catalent and will acquire Catalent in a deal valued at $16.5 billion.